Abstract 55P
Background
Treatment of heavily pre-treated metastatic breast cancer (MBC) involves several lines of chemotherapy however, favourable side effect profile and a convenient mode of administration are important. Eribulin, is with proven activity in aggressive MBC however, there is paucity of real-world data from India and merits exploration.
Methods
We retrospectively analyzed, previously treated MBC patients who had at least 2 lines of prior therapy and received intravenous Eribulin at the dose of 1.4 mg/m2 on day 1 and 8 in 3 weekly cycles, between 2013 and 2019. To describe the clinical performance of eribulin we adopted the approach suggested by Dzimitrowicz and colleagues (J Clin Oncol. 2016; 34:3511e17); Tumour Response (TR) was defined as the proportion of physician-reported clinical or imaging (RECIST) response. Furthermore, we evaluated median Progression Free (PFS) and Overall Survival (OS) by the Kaplan Meier method. The patients were monitored for toxicity by CTCAE 4.3 criteria.
Results
There were 78 patients with the median age of 53 (32-75) years, 2 (2.6%) had male breast cancer. The median number of previous chemotherapy lines was 5(2-7); visceral involvement was present in 76 (97.4%) patients with median of 3 organs (range 0-6) involvement and bones (61.5%) being most common site followed by lung (52.5%). A median of 3.5 (1-11) cycles of eribulin was administered. TR seen as partial responses in 35 (44.9%), stable disease in 9 (11.5%), and progressive disease in 34 (43.6%) patients. The median PFS was 3.0 months (95% CI: 2.2-3.8), and median OS was 7 (95% CI: 5.1-8.9) months. Interestingly, eribulin activity was unrelated to the number of previous lines and type of metastatic involvement. Eribulin was well tolerated with only 2 (2.5%) patients discontinuing therapy due to toxicity. Significant grade 3/4 toxicities seen included peripheral neuropathy in 10 (12.8%) which peaked after 6 cycles and neutropenia in 17 (21.8%) of patients while dose reductions were required in 6 (7.7%) of patients.
Conclusions
In this relatively large, single Institution, real practice analysis eribulin is an efficacious, safe and easy to administer option for pre-treated MBC and merits consideration.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
434P - Pan-Canadian evidence-based, consensus-driven cancer treatment protocols/information for use at the point of care by medical oncologists? Is there a need?
Presenter: Kiran Virik
Session: e-Poster Display Session
435P - Hypnotics and risk of cancer: A meta-analysis of observational studies
Presenter: Tzu Rong Peng
Session: e-Poster Display Session
436P - Clinicopathological characteristics and outcomes of adolescent and young adult (AYA) melanoma: Results from an Asian perspective
Presenter: Wei Lin Goh
Session: e-Poster Display Session
437P - Long-term efficacy and toxicity outcome of adjuvant external beam radiotherapy for medullary thyroid cancer: A single institution cohort study
Presenter: Ka Man Cheung
Session: e-Poster Display Session
438P - Real-world data of relapse after adjuvant treatment (Tx) in high-risk melanoma
Presenter: Carolina Ortiz Velez
Session: e-Poster Display Session
439P - Immunohistochemical analysis of p53 and Ki-67 in glioblastoma (GBM) and their correlations with patient survival
Presenter: Paulo Luz
Session: e-Poster Display Session
440P - Blinded independent central review of oncology trials: The monitoring of readers' performance
Presenter: Hubert Beaumont
Session: e-Poster Display Session
441P - Influence of radiation therapy of patients with somatotropic pituitary adenomas depending on the age of patients
Presenter: Saodat Issaeva
Session: e-Poster Display Session
442P - Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC)
Presenter: Bhumsuk Keam
Session: e-Poster Display Session